NanoValent Pharmaceuticals, Inc. (NVP), founded in 2006, is a privately-held company collaborating with the Children’s Hospital Los Angeles (CHLA) as well as other US academic partners to develop novel therapeutic options with enhanced target and delivery characteristics. NanoValent possesses a highly experienced core management team with a proven track record of success, supported by a strong clinical and operational support group.
NVP has so far developed three HPLN (Hybrid Polymerized Liposomal Nanoparticle) based candidates in oncology in close collaboration with CHLA: NV101, NV102 and NV103. These first NVP candidates (NV101 (Doxorubicin-anti-CD99), NV102 (Doxorubicin-anti-CD19) and NV103 (Irinotecan-anti-CD99) are approaching phase 1 and validating programs in Ewing sarcoma (with NV101 and NV103) are underway. A further program in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is also envisaged with NV102. In addition NVP has developed with Boston University the highly novel NV201, a fibrin targeted, PSM (Polymerized Shell Microbubble) ultrasound activated project that shows early promise in diagnosing and treating surgical adhesions.
Our technology promises to enables significant enhancement of the performance of therapeutic agents. For example, NV102 increases tumor-killing efficacy 10-12 fold in vitro, compared to untargeted HPLN loaded with Doxorubicin and almost 40 fold versus conventional Doxorubicin. With NV101 the enhancement seen has been even greater, 40 fold versus commercially available Doxo-liposomes and 80 fold versus Doxorubicin. We are already seeing similar, perhaps greater, potential of enhanced power and control in NV103 versus already approved benchmark products, and have therefore decided to make this our leading candidate. Once we achieve basic clinical validation in NV103 NanoValent will progress as a company able to apply our IP to various challenges, both in adult oncology and beyond.